A landscape analysis and discussion of value of gene therapies for sickle cell disease-Reference-Cited by-同舟云学术

A landscape analysis and discussion of value of gene therapies for sickle cell disease

Published:2022-04-18 Issue:6 Volume:22 Page:891-911
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Quach Dalyna¹,Jiao Boshen¹,Basu Anirban¹²,Bender M.A.³⁴,Hankins Jane⁵,Ramsey Scott³,Devine Beth¹²

Affiliation:

1. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington

2. Department of Health Services, University of Washington, Seattle, Washington, United States

3. Division of Public Health Sciences and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle

4. Department of Pediatrics, University of Washington, and Clinical Research Division,Fred Hutchinson Cancer Research Center, Seattle

5. Department of Hematology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

Funder

This research was funded by the National Heart, Lung and Blood Institute, Cure Sickle Cell initiative

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.2060823

Reference51 articles.

1. Gene Therapy: Promises, Problems and Prospects

2. Gene Therapy in a Patient with Sickle Cell Disease

3. New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?

4. Cure sickle cell initiative | advancing research in sickle cell disease | cure sickle cell. curesickle.org. https://curesickle.org/. Published. 2021 2021 Jun 24.

5. Gene therapy: advances, challenges and perspectives

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States;Annals of Internal Medicine;2024-02

2. The APC-EPCR-PAR1 axis in sickle cell disease;Frontiers in Medicine;2023-07-11

3. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance;Blood Advances;2023-01-27

4. Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment;Clinical Laboratory;2023

5. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials;Expert Opinion on Emerging Drugs;2022-04-03